[go: up one dir, main page]

AR042534A1 - Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa - Google Patents

Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa

Info

Publication number
AR042534A1
AR042534A1 ARP030104713A ARP030104713A AR042534A1 AR 042534 A1 AR042534 A1 AR 042534A1 AR P030104713 A ARP030104713 A AR P030104713A AR P030104713 A ARP030104713 A AR P030104713A AR 042534 A1 AR042534 A1 AR 042534A1
Authority
AR
Argentina
Prior art keywords
inhibitor
hmg
transfer protein
cholesterile
glutaril
Prior art date
Application number
ARP030104713A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR042534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR042534A1 publication Critical patent/AR042534A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación comprende (1) una dispersión sólida amorfa que comprende un inhibidor de la proteína de transferencia de ésteres de colesterilo (Torcetrapib, entre otros) y un polímero ácido potenciador de la concentración, y (2) un inhibidor de la HMG-CoA-reductasa (Atorvastatina, entre otros). La dispersión sólida amorfa y el inhibidor de la HMG-CoA-reductasa se combinan en la forma de dosificación de modo que la dispersión sólida amorfa y el inhibidor de la HMG-CoA-reductasa están sustancialmente separados entre sí en la forma de dosificación y método de preparación de la forma de dosificación unitaria.
ARP030104713A 2002-12-20 2003-12-18 Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa AR042534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43534502P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
AR042534A1 true AR042534A1 (es) 2005-06-22

Family

ID=32682223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104713A AR042534A1 (es) 2002-12-20 2003-12-18 Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa

Country Status (24)

Country Link
US (1) US7897175B2 (es)
EP (1) EP1581210B1 (es)
JP (1) JP2006512359A (es)
KR (1) KR20050088190A (es)
CN (1) CN1728995A (es)
AR (1) AR042534A1 (es)
AT (1) ATE389396T1 (es)
AU (1) AU2003286372A1 (es)
BR (1) BR0317593A (es)
CA (1) CA2509688A1 (es)
CO (1) CO5590898A2 (es)
DE (1) DE60319877T2 (es)
ES (1) ES2300628T3 (es)
GT (1) GT200300295A (es)
IL (1) IL169090A0 (es)
NL (1) NL1025070C (es)
NO (1) NO20052779L (es)
PE (1) PE20040970A1 (es)
PL (1) PL377606A1 (es)
RU (1) RU2005119176A (es)
TW (1) TW200420301A (es)
UY (1) UY28134A1 (es)
WO (1) WO2004056359A1 (es)
ZA (1) ZA200504123B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006129167A1 (en) * 2005-05-31 2006-12-07 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
CA2618255C (en) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
PL1912626T3 (pl) * 2005-08-08 2016-10-31 Postaci użytkowe o polepszonej biodostępności
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
KR100791256B1 (ko) * 2006-03-17 2008-01-03 주식회사 대웅제약 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US20100029743A1 (en) * 2006-09-27 2010-02-04 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
WO2008065506A2 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
PE20140018A1 (es) 2010-11-04 2014-01-31 Hoffmann La Roche Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3185869A1 (en) * 2014-08-28 2017-07-05 Dezima Pharma B.V. PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
DE69324504T2 (de) 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
DE69624564T2 (de) * 1995-06-01 2003-03-20 G.D. Searle & Co., Chicago Misoprostolhaltige feste stabilisierte dispersionen
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
ATE250929T1 (de) * 1997-05-30 2003-10-15 Osmotica Corp Mehrlagige osmosevorrichtung
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6462091B1 (en) * 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
EP1970052A2 (en) * 1999-02-09 2008-09-17 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
HRP20020950A2 (en) * 2000-06-09 2004-12-31 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
BR0113200A (pt) * 2000-08-15 2003-09-16 Pfizer Prod Inc Combinação terapêutica
US20020077348A1 (en) 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
EP1395254B1 (en) * 2001-06-12 2007-04-04 Galephar M/F Oral pharmaceutical composition containing a statin derivative
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
JP2006512359A (ja) 2006-04-13
DE60319877D1 (de) 2008-04-30
WO2004056359A1 (en) 2004-07-08
NL1025070A1 (nl) 2004-06-22
ZA200504123B (en) 2006-02-22
KR20050088190A (ko) 2005-09-02
AU2003286372A1 (en) 2004-07-14
CN1728995A (zh) 2006-02-01
US20040197398A1 (en) 2004-10-07
EP1581210A1 (en) 2005-10-05
NL1025070C (nl) 2010-04-06
PL377606A1 (pl) 2006-02-06
ATE389396T1 (de) 2008-04-15
ES2300628T3 (es) 2008-06-16
UY28134A1 (es) 2004-07-30
NO20052779D0 (no) 2005-06-08
EP1581210B1 (en) 2008-03-19
CO5590898A2 (es) 2005-12-30
DE60319877T2 (de) 2009-04-30
RU2005119176A (ru) 2006-01-20
US7897175B2 (en) 2011-03-01
GT200300295A (es) 2004-08-18
TW200420301A (en) 2004-10-16
IL169090A0 (en) 2007-07-04
NO20052779L (no) 2005-08-25
PE20040970A1 (es) 2004-12-14
BR0317593A (pt) 2005-11-22
CA2509688A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AR042534A1 (es) Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
UY26864A1 (es) Composiciones farmaceúticas de inhibidores de la proteína de transferencia de colesteril éster
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
FR14C0064I2 (fr) Anticorps anti-il-6, compositions, methodes et utilisations associees
BR0317715A (pt) Composições e processos de uso de collajolie
NO20065329L (no) Fremstilling av pregabalin og beslektede forbindelser.
DE602005016532D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
DE602005015686D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
HN1998000002A (es) Compuestos de quinolina y de quinazolina utiles en terapia
AU2003266161A1 (en) High concentration topical insecticide
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
AU2003251529A1 (en) Planetarium and point light source for the use in same
AU2003215175A1 (en) Fluorescent phospholipase assay, phospholipase a2 inhibitor and stimulator, and the use thereof
BRPI0417138A (pt) n-alquil-pirroles como inibidores de hmg-coa-redutase
BR0316544A (pt) Compostos calcilìticos
ID24306A (id) Turunan asam kuinolin-2 karboksilat dan penggunaannya sebagai antagonis asam amino eksitatori
EA200200798A1 (ru) Кальцилитические соединения
BR0114884A (pt) Compostos calcilìticos
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
WO2003087051A3 (en) Methods for identifying allosteric sites
DOP2003000797A (es) Formas de dosificacion que comprenden un inhibidor de la ptec y un inhbidor de la hmg-coa-reductasa
AU2003295595A1 (en) Spacer-less field emission display

Legal Events

Date Code Title Description
FB Suspension of granting procedure